Results | Latest & Breaking News on Results | Photos, Videos, Breaking Stories and Articles on Results

At Moneycontrol, the Results page helps you effectively track corporate announcements and results for various listed companies across both India and abroad. With our Results page, you can keep abreast with an updated, comprehensive view of all the profit/loss statements, company spendings, AGM outcomes, and quarterly and annual results from all these listed companies. Additionally, Moneycontrol also regularly tracks international MNCs listed on NASDAQ and Asian bourses, including popular companies like Apple, Google, Alibaba. Apart from finding solid copies of company results, stock movements consequent to these company results, expectations, and analytical post results copies, you will also find copies and articles detailing the earnings, impact, and all major announcements made to media/exchanges by these companies, so that you do not miss anything. We also provide you with concrete data points to help you spot profitable trades, stock build-ups, and bulk deals. At Moneycontrol, we also cover analysts/investors meetings; scrutinise results and data and BSE/NSE reports or news. The copies are not just full of information and data, but are also adequately supplemented with expert views, investor opinions, extensive interviews, videos, and a huge variety of explainers, analyses, and informative slideshows to help you gauge the market and make investment decisions in the best possible manner. More

Jump to

Natco Q1 PAT seen up 36.2% YoY to Rs 436.5 cr: Nirmal Bang

Net Sales are expected to increase by 35.1 percent Y-o-Y (up 33.1 percent Q-o-Q) to Rs 1,195.4 crore, according to Nirmal Bang.
Natco Q3 PAT may dip 24% YoY to Rs. 165 cr: Sharekhan

Net Sales are expected to decrease by 5 percent Y-o-Y (down 1.8 percent Q-o-Q) to Rs. 534 crore, according to Sharekhan.
Natco Pharma Q3 PAT may dip 30.3% YoY to Rs. 151.7 cr: ICICI Direct

Net Sales are expected to decrease by 4.9 percent Y-o-Y (down 1.6 percent Q-o-Q) to Rs. 534.7 crore, according to ICICI Direct.
Natco Q2 PAT seen up 78.6% YoY to Rs. 150 cr: Sharekhan

Net Sales are expected to increase by 20 percent Y-o-Y (down 4.9 percent Q-o-Q) to Rs. 512 crore, according to Sharekhan.
Advertisement
Remove Ad
Advertisement
Remove Ad
Advertisement
Remove Ad
Advertisement
Remove Ad
Natco Pharma Q2 PAT seen up 118.2% YoY to Rs. 185 cr: ICICI Direct

Net Sales are expected to increase by 31.3 percent Y-o-Y (up 4 percent Q-o-Q) to Rs. 560.1 crore, according to ICICI Direct.
Natco Pharma Q4 PAT seen up 78.5% YoY to Rs. 315.3 cr: Edelweiss

Net Sales are expected to increase by 29 percent Y-o-Y (up 30.5 percent Q-o-Q) to Rs. 745.1 crore, according to Edelweiss.
Pharma Q4 earnings preview: Tough quarter; US pricing pressure, domestic sales recovery hold key

Analysts predict the last quarter of FY18 to be mixed bag with revenues expected to remain almost flat to a growth of lower single digit on year-on-year basis. The net profit is predicted to decline by around 9-10 percent.
Pharma Q3 earnings preview - cos brace for challenging quarter, US and India sales hold key

As Indian drug makers brace up to report their third quarter earnings in the days ahead, analysts predict Q3 FY18 to be mixed bag with revenues expected to remain flat on year-on-year basis, though on sequential basis things may look much better.
Advertisement
Remove Ad
Natco Pharma Q4 PAT may dip 26.8% to Rs 156.1 cr: ICICI Securities

Net Sales are expected to decrease by 18.5 percent Q-o-Q (up 36 percent Y-o-Y) to Rs 553.4 crore, according to ICICI Securities. Natco Pharma to report net profit at 156.1 crore down 26.8% quarter-on-quarter.
Natco Pharma Q3 PAT seen up 6.1% to Rs 70.3 cr: ICICI Securities

Net Sales are expected to decrease by 1.8 percent Q-o-Q (up 66.4 percent Y-o-Y) to Rs 459.3 crore, according to ICICI Securities.
Pharma biz to drive Jubilant Life's future growth: Surajit Pal

Jubilant Life Sciences working on reducing its debt through internal accruals against taking fresh loan will serve well for its future growth says Surajit Pal, Prabhudas Lilladher.
Natco Pharma Q1 PAT seen down by 24.1% at Rs 45.7 cr: Religare

Sales are expected to decrease by 20.6 percent Q-o-Q (up 44.4 percent Y-o-Y) to Rs 323.0 crore, according to Religare Research.
Advertisement
Remove Ad
Natco Pharma Q1 PAT seen down 34.1% to Rs 39.7 cr: Edelweiss

Net Sales are expected to decrease by 29 percent Q-o-Q (up 29.1 percent Y-o-Y) to Rs 288.8 crore, according to Edelweiss
Pharma companies revenues to rise 12% in Q3: Anand Rathi

Pharma companies are likely to post 12 percent Y-o-Y revenue growth. However, excluding Wockhardt (FDA issues) and Fortis Healthcare (divestments), revenue growth is expected to be 19 percent Y-o-Y.

Patent win against Teva to boost revenues: Natco Pharma

Bhaskar Narayana, Finance Director & CFO, Natco Pharma is confident of maintaining the current growth rate in terms of margins going forward.
See Rs 20-25cr in revenue/quarter from Lanzoprazol: Natco

Hyderabad-based Natco Pharma Limited, on December 21, received the approval from Food & Drug Administration (FDA) for marketing the prescription version of Lanzoprazole, CFO of the company Bhaskar Narayana told CNBC-TV18 in an interview.